SCHEDULE 13G/A: BlackRock Discloses 6.2% Passive Stake in AnaptysBio Inc.
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 1,900,844 shares of AnaptysBio Inc. common stock.
- This ownership represents 6.2% of AnaptysBio Inc.'s outstanding common stock.
- BlackRock holds sole voting power over 1,880,093 shares and sole dispositive power over 1,900,844 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of AnaptysBio Inc.
- Various BlackRock subsidiaries and affiliates, including BlackRock Investment Management, LLC, are involved in the beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a factual, compliance-driven filing disclosing beneficial ownership, with no explicit positive or negative operational or financial news for the issuer.
Positives
- The disclosure of a significant stake by a major institutional investor like BlackRock, Inc. can be viewed as a vote of confidence in AnaptysBio Inc.
Industry Context
This filing represents a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, regarding its passive investment in AnaptysBio Inc., a biotechnology company. Such disclosures are standard for institutional investors holding significant stakes in publicly traded companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney. |
| 01/21/2025 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires the filing of this statement (reporting period end). |
| 04/17/2025 | Date the Schedule 13G Amendment No. 8 was signed and filed. |
Keywords
BlackRock, AnaptysBio, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.